FrancophonIA/ELRC3.0 huggingface dataset:
English: The European Medicines Agency therefore decided that Sevelamer carbonate Winthrop's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Sevelamer carbonate Winthrop večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Sevelamer carbonate Winthrop is available as tablets (800 mg) and as powder (800 mg and 2.4 g) to be taken 3 times a day with meals.
Slovenian: Zdravilo Sevelamer carbonate Winthrop je na voljo v obliki tablet (800 mg) ali praška (800 mg in 2,4 g) in se jemlje trikrat na dan z obroki.
English: When taken with meals, it attaches in the gut to phosphate from the food, thereby preventing the phosphate from being absorbed into the body and helping to reduce phosphate levels in the blood.
Slovenian: Ko se vzame s hrano, se v črevesju veže na fosfat iz hrane, kar preprečuje njegovo absorpcijo v telo in prispeva k zmanjšanju njegovih ravni v krvi.
English: Sevelamer carbonate Winthrop received a marketing authorisation valid throughout the EU on 15 January 2015.
Slovenian: Za zdravilo Sevelamer carbonate Winthrop je bilo 15. januarja 2015 izdano dovoljenje za promet, veljavno po vsej EU.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sevelamer carbonate Winthrop have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Sevelamer carbonate Winthrop upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Sevelamer carbonate Winthrop must not be taken on an empty stomach and patients should keep to their prescribed diets.
Slovenian: Zdravilo Sevelamer carbonate Winthrop se ne sme jemati na prazen želodec, bolniki pa morajo upoštevati predpisano dieto.
English: The dose to take depends on the patient's level of blood phosphate and, for children, their height and weight.
Slovenian: Odmerek je odvisen od bolnikove ravni fosfata v krvi, pri otrocih pa od telesne višine in mase.
English: The most common side effects with Sevelamer carbonate Winthrop (which may affect more than 1 in 10 people) are nausea (feeling sick), vomiting, upper abdominal (belly) pain and constipation.
Slovenian: Najpogostejši neželeni učinki zdravila Sevelamer carbonate Winthrop (ki se lahko pojavijo pri več kot 1 od 10 bolnikov) so navzeja (siljenje na bruhanje), bruhanje, bolečine v zgornjem predelu trebuha in zaprtje.
English: In a third main study in 49 adults who were not on dialysis, Sevelamer carbonate Winthrop reduced phosphate levels from 2.0 mmol/l to 1.6 mmol/l.
Slovenian: V tretji glavni študiji pri 49 odraslih, ki niso bili na dializi, je zdravilo Sevelamer carbonate Winthrop znižalo ravni fosfata z 2,0 mmol/l na 1,6 mmol/l.
English: Sevelamer carbonate Winthrop should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Slovenian: Zdravilo Sevelamer carbonate Winthrop je treba uporabljati sočasno z drugimi zdravili, na primer z dodatki kalcija in vitamina D, za preprečevanje razvoja bolezni kosti.
English: For more information about using Sevelamer carbonate Winthrop, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Sevelamer carbonate Winthrop glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: In two main studies in 110 adults with kidney disease who were on dialysis, Sevelamer carbonate Winthrop brought phosphate levels down to around 1.5-1.6 mmol/l (which is within or close to the normal range) and was as effective as another approved medicine Renagel.
Slovenian: V dveh glavnih študijah pri 110 odraslih z obolenjem ledvic, ki so bili na dializi, je zdravilo Sevelamer carbonate Winthrop znižalo ravni fosfata na približno 1,5-1,6 mmol/l (kar je znotraj oziroma blizu normalnega razpona) in je bilo enako učinkovito kot drugo, že odobreno zdravilo, in sicer zdravilo Renagel.
English: Side effects reported with Sevelamer carbonate Winthrop are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Sevelamer carbonate Winthrop, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: 1 Previously known as Sevelamer carbonate Zentiva.
Slovenian: 1 Prej znano pod imenom Sevelamer carbonate Zentiva.
English: What measures are being taken to ensure the safe and effective use of Sevelamer carbonate Winthrop?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Sevelamer carbonate Winthrop?
English: As for all medicines, data on the use of Sevelamer carbonate Winthrop are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Sevelamer carbonate Winthrop stalno spremljajo.
English: An overview of Sevelamer carbonate Winthrop and why it is authorised in the EU
Slovenian: Pregled zdravila Sevelamer carbonate Winthrop in zakaj je odobreno v EU
English: Finally, a main study also showed that Sevelamer carbonate Winthrop was effective at lowering phosphate levels in 100 children: children who took Sevelamer carbonate Winthrop had a greater reduction in phosphorous (0.87 mg/dl) than those taking placebo (a dummy treatment) who had a rise in phosphorous of 0.04 mg/dl.
Slovenian: V še eni glavni študiji pri 100 otrocih so ugotovili, da je zdravilo Sevelamer carbonate Winthrop učinkovito pri zniževanju ravni fosfata, saj se je raven fosforja pri otrocih, ki so jemali to zdravilo, zmanjšala bolj (0,87 mg/dl) kot pri bolnikih, ki so jemali placebo (zdravilo brez učinkovine), pri katerih se je vrednost fosforja zvišala za 0,04 mg/dl.
English: Sevelamer carbonate Winthrop is a medicine used to control hyperphosphataemia (high blood phosphate levels) in:
Slovenian: Sevelamer carbonate Winthrop je zdravilo, ki se uporablja za obvladovanje hiperfosfatemije (visoke ravni fosfata v krvi) pri:
English: The active substance in Sevelamer carbonate Winthrop, sevelamer carbonate, is a phosphate binder.
Slovenian: Učinkovina v zdravilu Sevelamer carbonate Winthrop, sevelamerijev karbonat, je vezalec fosfata.
English: Studies show that Sevelamer carbonate Winthrop is effective at reducing levels of blood phosphate in patients with hyperphosphataemia, and its side effects are considered manageable.
Slovenian: V študijah so ugotovili, da je zdravilo Sevelamer carbonate Winthrop učinkovito pri zniževanju ravni fosfata v krvi pri bolnikih s hiperfosfatemijo, njegovi neželeni učinki pa se štejejo za obvladljive.
English: What benefits of Sevelamer carbonate Winthrop have been shown in studies?
Slovenian: Kakšne koristi zdravila Sevelamer carbonate Winthrop so se pokazale v študijah?
English: Sevelamer carbonate Winthrop must not be used in people with low blood phosphate levels or with bowel obstruction (a blockage in the gut).
Slovenian: Zdravilo Sevelamer carbonate Winthrop se ne sme uporabljati pri osebah z nizko ravnjo fosfata v krvi ali obstrukcijo (zaporo) črevesa.
English: What is Sevelamer carbonate Winthrop and what is it used for?
Slovenian: Kaj je zdravilo Sevelamer carbonate Winthrop in za kaj se uporablja?
English: It contains the active substance sevelamer carbonate.
Slovenian: Vsebuje učinkovino sevelamerijev karbonat.
English: Why is Sevelamer carbonate Winthrop approved?
Slovenian: Zakaj je bilo zdravilo Sevelamer carbonate Winthrop odobreno?
English: Other information about Sevelamer carbonate Winthrop
Slovenian: Druge informacije o zdravilu Sevelamer carbonate Winthrop
English: (sevelamer carbonate)
Slovenian: (sevelamerijev karbonat)
English: For the full list of side effects of Sevelamer carbonate Winthrop, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Sevelamer carbonate Winthrop, glejte navodilo za uporabo.
English: What are the risks associated with Sevelamer carbonate Winthrop?
Slovenian: Kakšna tveganja so povezana z zdravilom Sevelamer carbonate Winthrop?
English: Sevelamer carbonate Winthrop has been shown in studies to be effective at lowering levels of blood phosphate in patients with hyperphosphataemia.
Slovenian: V študijah so dokazali, da je zdravilo Sevelamer carbonate Winthrop učinkovito pri zniževanju ravni fosfata v krvi pri bolnikih s hiperfosfatemijo.
English: How does Sevelamer carbonate Winthrop work?
Slovenian: Kako zdravilo Sevelamer carbonate Winthrop deluje?
English: How is Sevelamer carbonate Winthrop used?
Slovenian: Kako se zdravilo Sevelamer carbonate Winthrop uporablja?
English: Date of first authorisation: 21 April 2016
Slovenian: Datum prve odobritve: 21. april 2016
English: Effect is unknown.
Slovenian: Učinek ni znan.
English: ATC code: J05AR17.
Slovenian: Oznaka ATC: J05AR17.
English: Keep the tablet bottle with you so that you can show what you have taken.
Slovenian: S seboj imejte plastenko tablet, da boste pokazali, kaj ste zaužili.
English: None of the changes was considered clinically relevant.
Slovenian: Nobena od sprememb ni bila ocenjena za klinično pomembno.
English: Adults: one tablet each day, with or without food
Slovenian: Odrasli: ena tableta vsak dan s hrano ali brez nje
English: This is because one of the active substances in this medicine passes into breast milk.
Slovenian: To je zato, ker ena učinkovina tega zdravila prehaja v mleko.
English: Other types of medicine:
Slovenian: Druge vrste zdravil:
English: Descovy therefore reduces the amount of HIV in your body.
Slovenian: Zdravilo Descovy zato zmanjša količino virusa HIV v vašem telesu.
English: The film-coated tablet should not be chewed, crushed, or split.
Slovenian: Filmsko obložene tablete se ne sme žvečiti, zdrobiti ali razdeliti.
English: If you have taken Descovy during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child.
Slovenian: Če ste zdravilo Descovy jemali med nosečnostjo, vas lahko zdravnik naroči na redne preiskave krvi in druge diagnostične preiskave, da bo spremljal razvoj vašega otroka.
English: Talk to your doctor if you are taking:
Slovenian: Obvestite svojega zdravnika, če jemljete:
English: Treatment difference
Slovenian: Razlika zdravljenja
English: No emergent resistance to E/C/F/TAF was detected through Week 48.
Slovenian: Pojava rezistence proti E/C/F/TAF do vključno 48. tedna niso odkrili.
English: If you feel dizzy when taking Descovy, do not drive and do not use any tools or machines.
Slovenian: Če se vam med zdravljenjem z zdravilom Descovy pojavlja omotičnost, ne vozite avtomobila in ne upravljajte orodij ali strojev.
English: Race Black Non-black
Slovenian: Črnci Ne črnci
English: Descovy should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Slovenian: Zdravilo Descovy se sme med nosečnostjo uporabljati samo, če možne koristi upravičujejo možno tveganje za plod.
English: • Your doctor may not prescribe Descovy to you if the virus has a K65R mutation.
Slovenian: • Zdravnik vam morda ne bo predpisal zdravila Descovy, če ima virus mutacijo K65R.
English: • antibiotics, used to treat bacterial infections including tuberculosis, containing:
Slovenian: • antibiotike, ki se uporabljajo za zdravljenje bakterijskih okužb, vključno s tuberkulozo, ki vsebujejo:
English: Treatment of overdose with Descovy consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient.
Slovenian: Zdravljenje prevelikega odmerka z zdravilom Descovy načeloma predstavljajo podporni ukrepi, vključno s spremljanjem vitalnih znakov in opazovanjem kliničnega stanja bolnika.
English: Therefore, the same problems may be seen if Descovy is administered with a third nucleoside analogue.
Slovenian: Zato je mogoče, da se bodo enake težave pojavile pri zdravilu Descovy, če se bo uporabilo s tretjim nukleozidnim analogom.
English: Stopping Descovy can seriously affect how well future treatment works.
Slovenian: Prenehanje jemanja zdravila Descovy lahko resno vpliva na to, kako dobro bo delovalo prihodnje zdravljenje.
English: 2 When data are available from drug-drug interaction studies.
Slovenian: 2 Ko so razpoložljivi podatki iz študij medsebojnega delovanja zdravil.
English: What Descovy is and what it is used for
Slovenian: Kaj je zdravilo Descovy in za kaj ga uporabljamo
English: Descovy contains two active substances:
Slovenian: Zdravilo Descovy vsebuje dve učinkovini:
English: In animal studies it has been shown that tenofovir is excreted in milk.
Slovenian: Študije na živalih so pokazale, da se tenofovir izloča v mleko.
English: • If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Slovenian: Nosečnost in dojenje • Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden vzamete to zdravilo.
English: Descovy should be taken orally, once daily with or without food (see section 5.2).
Slovenian: Zdravilo Descovy se jemlje enkrat dnevno, peroralno s hrano ali brez nje (glejte poglavje 5.2).
English: 5 Study conducted with Descovy.
Slovenian: 5 Študija je bila opravljena z zdravilom Descovy.
English: As a result, the amounts of Descovy or other medicines in your blood may change.
Slovenian: To lahko posledično spremeni količino zdravila Descovy ali drugih zdravil v vaši krvi.
English: If you have both HIV infection and hepatitis B, it is very important not to stop taking Descovy without talking to your doctor first.
Slovenian: Če ste okuženi tako z virusom HIV kot s hepatitisom B, je zelo pomembno, da ne prenehate jemati zdravila Descovy, ne da bi se prej posvetovali z zdravnikom.
English: The 50% effective concentration (EC50) values for emtricitabine were in the range of 0.0013 to 0.64 μM.
Slovenian: Vrednosti 50-odstotno učinkovite koncentracije (EC50) za emtricitabin so bile v razponu od 0,0013 do 0,64 µM.
English: Descovy may interact with other medicines.
Slovenian: Zdravilo Descovy lahko medsebojno deluje z drugimi zdravili.
English: The use of Descovy in children aged 11 years or under has not yet been studied.
Slovenian: Uporabe zdravila Descovy pri otrocih, starih 11 let ali manj, še niso preučili.
English: If Descovy is stopped for any reason, speak to your doctor before you restart taking Descovy tablets.
Slovenian: Če zaradi katerega koli razloga prenehate jemati zdravilo Descovy, se pogovorite s svojim zdravnikom, preden začnete ponovno jemati tablete zdravila Descovy.
English: 7 Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposurers expected in HCV-infected patients.
Slovenian: 7 Študija je bila opravljena z dodatnim voksilaprevirjem 100 mg za doseganje izpostavljenosti voksilaprevirju, pričakovane pri bolnikih, okuženih s HCV.
English: There are no adequate and well-controlled studies of Descovy or its components in pregnant women.
Slovenian: Ni ustreznih, dobro kontroliranih študij z zdravilom Descovy ali njegovimi učinkovinami pri nosečnicah.
English: Ethinylestradiol:
Slovenian: etinilestradiol:
English: If you have hepatitis B liver problems may become worse after you stop taking Descovy.
Slovenian: Če imate hepatitis B, se lahko težave z jetri poslabšajo, ko prenehate jemati zdravilo Descovy.
English: Iron oxide black (E172)
Slovenian: smukec črni železov oksid (E172)
English: Once you start taking Descovy, look out for:
Slovenian: Ko začnete jemati zdravilo Descovy, bodite pozorni na:
English: It is recommended that you do not breast-feed to avoid passing the virus to the baby through breast milk.
Slovenian: Priporočljivo je, da ne dojite, da s tem preprečite prenos virusa z mlekom na dojenčka.
English: At baseline, median eGFR was 56 mL/min, and 33% of patients had an eGFR from 30 to 49 mL/min.
Slovenian: Na začetku je bila mediana eGFR 56 ml/min, 33 % bolnikov pa je imelo vrednost eGFR od 30 do 49 ml/min.
English: Ex vivo binding of tenofovir alafenamide to human plasma proteins in samples collected during clinical studies was approximately 80%.
Slovenian: Ex vivo vezava tenofoviralafenamida na humane plazemske proteine v vzorcih, odvzetih med kliničnimi študijami, je bila približno 80 %.
English: In some patients with advanced HIV infection (AIDS) and who have had opportunistic infections in the past (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after antiretroviral treatment is started.
Slovenian: Pri nekaterih bolnikih z napredovalo okužbo s HIV (AIDSom) in tistih, ki so imeli oportunistične okužbe v preteklosti (okužbe, ki se pojavijo pri ljudeh z oslabljenim imunskim sistemom), se lahko znaki in simptomi vnetja zaradi prejšnjih okužb pojavijo kmalu po začetku protiretrovirusnega zdravljenja.
English: Pharmacotherapeutic group: Antiviral for systemic use; antivirals for treatment of HIV infections, combinations.
Slovenian: Farmakoterapevtska skupina: zdravilo za sistemsko zdravljenje virusnih infekcij, zdravila za zdravljenje infekcij s HIV, kombinacije.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with Descovy in one or more subsets of the paediatric population in the treatment of HIV-1 infection (see section 4.2 for information on paediatric use).
Slovenian: Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Descovy za eno ali več podskupin pediatrične populacije za zdravljenje okužbe z virusom HIV-1 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: Adolescents 12 years of age and older, who weigh at least 35 kg: one tablet each day with or without food Do not chew, crush or split the tablet.
Slovenian: Mladostniki, stari 12 let ali več, s telesno maso vsaj 35 kg: ena tableta vsak dan s hrano ali brez nje Tablete ne žvečite, drobite in ne delite.
English: Tipranavir/ritonavir results in P-gp induction.
Slovenian: Tipranavir/ritonavir ima za posledico indukcijo P-gp.
English: Interaction not studied with either of the components of Descovy.
Slovenian: Interakcij niso preučili z nobeno od učinkovin zdravila Descovy.
English: No data are available to make dose recommendations in children less than 18 years with end stage renal disease.
Slovenian: Ni podatkov za dajanje priporočil o odmerjanju pri otrocih, starih manj kot 18 let s končno ledvično odpovedjo.
English: 2 This adverse reaction was not observed in the clinical studies of F/TAF-containing products but identified from clinical studies or post-marketing experience for emtricitabine when used with other antiretrovirals.
Slovenian: 2 Tega neželenega učinka niso opazili v kliničnih študijah za zdravila, ki vsebujejo F/TAF, temveč je bil opredeljen v kliničnih študijah ali izkušnjah v obdobju trženja za emtricitabin pri uporabi z drugimi protiretrovirusnimi zdravili.
English: If you vomit less than 1 hour after taking Descovy, take another tablet.
Slovenian: Če bruhate manj kot 1 uro po zaužitju zdravila Descovy, vzemite še eno tableto.
English: If you are on dialysis, take your daily dose of Descovy following completion of dialysis.
Slovenian: Če ste na dializi, vzemite svoj dnevni odmerek zdravila Descovy po končani dializi.
English: The safety and efficacy of Descovy in patients co-infected with HIV-1 and hepatitis C virus (HCV) have not been established.
Slovenian: Varnost in učinkovitost zdravila Descovy pri bolnikih s hkratno okužbo s HIV-1 in hepatitisa C (HCV) nista bili dokazani.
English: If you forget to take Descovy
Slovenian: Če ste pozabili vzeti zdravilo Descovy
English: • antiviral medicines used to treat HIV:
Slovenian: • zdravila za zdravljenje virusnih okužb, ki se uporabljajo za zdravljenje HIV:
English: Interactions between the components of Descovy and potential co-administered medicinal products are listed in Table 2 (increase is indicated as “↑”, decrease as “↓”, no change as “↔”).
Slovenian: Interakcije med učinkovinami zdravila Descovy in možnimi sočasno uporabljenimi zdravili so navedene v preglednici 2 (povečanje je označeno z znakom “↑”, zmanjšanje z “↓”, brez spremembe z “↔”).
English: Some patients taking combination antiretroviral medicines such as Descovy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone).
Slovenian: Pri nekaterih bolnikih, ki jemljejo kombinirana protiretrovirusna zdravila, kot je zdravilo Descovy, se lahko pojavi bolezen kosti, imenovana osteonekroza (odmiranje kostnega tkiva kot posledica pomanjkanja oskrbe kosti s krvjo).
English: Emtricitabine and tenofovir alafenamide demonstrated synergistic antiviral activity in cell culture.
Slovenian: Emtricitabin in tenofoviralafenamid sta pokazala sinergijsko protivirusno aktivnost v celični kulturi.
English: No dose adjustment of sertraline is required.
Slovenian: Odmerka sertralina ni treba prilagajati.
English: Missing data during window but on study drug
Slovenian: V oknu podatki manjkajo, a uporablja študijsko zdravilo
English: Tenofovir is efficiently removed by haemodialysis with an extraction coefficient of approximately 54%.
Slovenian: Tenofovir se učinkovito odstrani s hemodializo s koeficientom estrakcije približno 54 %.
English: The adverse reactions in Table 3 are listed by system organ class and frequency.
Slovenian: Neželeni učinki v preglednici 3 so našteti po organskih sistemih in pogostnosti.
English: Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1,000 to
Slovenian: Pogostnost je definirana kot sledi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10) in občasni (≥ 1/1.000 do Preglednica 3: Seznam neželenih učinkov v obliki preglednice1 Pogostnost
English: Patients were stratified by the class of the third agent in their prior treatment regimen.
Slovenian: Bolniki so bili stratificirani glede na razred tretjega zdravila v predhodnem režimu zdravljenja.
English: The pharmacokinetics of emtricitabine have not been studied in subjects with hepatic impairment; however, emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited.
Slovenian: Farmakokinetičnih lastnosti emtricitabina pri preizkušancih z jetrno okvaro niso proučevali, vendar jetrni encimi emtricitabina ne presnavljajo v pomembnem obsegu, zato je vpliv jetrne okvare verjetno omejen.
English: The interactions described are based on studies conducted with Descovy, or the components of Descovy as individual agents and/or in combination, or are potential drug-drug interactions that may occur with Descovy.
Slovenian: Opisane interakcije temeljijo na študijah, izvedenih z zdravilom Descovy ali z učinkovinami zdravila Descovy, kot posamičnimi učinkovinami in/ali v kombinaciji, ali pa je možno medsebojno delovanje, ki se lahko pojavi z zdravilom Descovy.
English: Changes in measures of renal function
Slovenian: Spremembe v meritvah delovanja ledvic
English: Most HIV-1 isolates from patients in both treatment groups who developed resistance mutations to elvitegravir in integrase also developed resistance mutations to emtricitabine in RT.
Slovenian: Pri večini izolatov HIV-1 bolnikov v obeh skupinah zdravljenja, pri katerih so se razvile mutacije, povezane z rezistenco na elvitegravir v integrazi, so se razvile tudi mutacije proti emtricitabinu v RT.
English: Medicinal products that strongly affect P-gp and BCRP activity may lead to changes in tenofovir alafenamide absorption.
Slovenian: Zdravila, ki močno vplivajo na aktivnost BCRP in P-gp lahko povzročijo spremembe v absorpciji tenofoviralafenamida.
English: What you need to know before you take Descovy Do not take Descovy:
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Descovy Ne jemljite zdravila Descovy: